Cargando…
Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors
We sought to evaluate the outcomes of chronic phase (CP) chronic myeloid leukemia (CML) in an era where five tyrosine kinase inhibitors (TKIs) are commercially available for the treatment of CML. Records of patients diagnosed with CP CML, treated with TKIs and referred to our center were reviewed. B...
Autores principales: | Kong, Jee Hyun, Winton, Elliott F., Heffner, Leonard T., Gaddh, Manila, Hill, Brittany, Neely, Jessica, Hatcher, Angela, Joseph, Meena, Arellano, Martha, El-Rassi, Fuad, Kim, Audrey, Khoury, Jean Hanna, Kota, Vamsi K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290862/ https://www.ncbi.nlm.nih.gov/pubmed/32443762 http://dx.doi.org/10.3390/jcm9051542 |
Ejemplares similares
-
Managing acute promyelocytic leukemia in patients belonging to the Jehovah’s Witness congregation
por: Jillella, Anand P., et al.
Publicado: (2017) -
ERRATUM: Managing acute promyelocytic leukemia in patients belonging to the Jehovah’s Witness congregation
por: Jillella, Anand P., et al.
Publicado: (2019) -
Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
por: Rassi, Fuad El, et al.
Publicado: (2013) -
Update on Optimal Management of Acute Myeloid Leukemia
por: El Rassi, Fuad, et al.
Publicado: (2013) -
Cross-Domain Text Mining to Predict Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
por: Mehra, Nidhi, et al.
Publicado: (2022)